AstraZeneca (LON: AZN) and its global biologics research and development arm, MedImmune, have updated the timeline for their final analysis of the Phase III MYSTIC trial of Imfinzi (durvalumab) as a monotherapy and in combination with tremelimumab, the company announced on Monday.

MYSTIC is a randomised, open-label, multi-centre, global Phase III trial of Imfinzi monotherapy or Imfinzi in combination with tremelimumab in comparison to platinum-based standard of care chemotherapy as a treatment for patients with previously untreated epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) wild-type locally-advanced or metastatic (Stage IV) 1st-line non-small cell lung cancer (NSCLC).

The trial is being conducted in 167 centres across 17 countries, including the US, Canada, Russia, Australia, as well as parts of Asia, such as Japan, Korea, Thailand, Taiwan and Vietnam.

Primary endpoints of the study include progression-free survival in the combination arm, and overall survival in monotherapy and in combination.

According to current predictions, the final analysis of overall survival is expected in the second half of 2018, pushed back from expectations it would be ready in the first half of the year.